Citations

Clear

3942 citation(s) found for "To, Van".

Teflon or Ivalon®: A Scoping Review of Implants Used in Microvascular Decompression for Trigeminal Neuralgia
Jha, R. Tushar, Zavadskiy, Gleb, Loveren, Harry van , Pressman, Elliot , Kumar, Jay I. , Peto, Ivo , Gompel, Jamie J. Van , Agazzi, Siviero

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702679 Get It

Use of Endoscopic Technique in Resection of Trigeminal Schwannoma
Carlson, Matthew L. , Stokken, Janalee K., Huang, Alice E. , Choby, Garret , Dey, Jacob K. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702627 Get It

Juvenile Nasopharyngeal Angiofibroma: A Retrospective Institutional Surgical Case Series
Cohen-Cohen, Salomón , Link, Michael J., Janus, Jeffrey R. , Moore, Eric J. , Kasperbauer, Jan L. , Choby, Garret , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702544 Get It

Efficacy and Safety of Bevacizumab for Vestibular Schwannoma in Neurofibromatosis Type 2: A Systematic Review and Meta-analysis of Treatment Outcomes
Lu, Victor M. , Ravindran, Krishnan , Graffeo, Christopher S. , Perry, Avital , Link, Michael , Gompel, Jamie J. Van , Daniels, David J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702498 Get It

Predicting Pituitary Adenomas Consistency with Preoperative Magnetic Resonance Elastography
Cohen-Cohen, Salomón , Huston, John , Hughes, Joshua , Yin, Ziying , Ball, Matthew K. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702481 Get It

Recurrence of Rathke’s Cleft Cysts Based on Gross Total Resection of Cyst Wall: A Meta-analysis
Lu, Victor M. , Perry, Avital , Graffeo, Christopher S. , Ravindran, Krishnan , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702442 Get It

β-Catenin Preserves the Stem State of Murine Bone Marrow Stromal Cells Through Activation of EZH2
Sen, Buer , Paradise, Christopher R. , Sankaran, Jeyantt Srinivas , Styner, Maya , Meyer, Mark B. , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , Styner, Maya , Meyer, Mark , Rubin, Janet , van Wijnen, Andre J , van Wijnen, Andre J , Xie, Zhihui , Uzer, Gunes

Mayo Clinic

Journal of Bone and Mineral Research | February 5, 2020 | Volume: 35 | Issue: 6 | Pages: 1149-1162

10.1002/jbmr.3975 | PMID 32022326 Get It

ABSTRACT During bone marrow stromal cell (BMSC) differentiation, both Wnt signaling and the development of a rigid cytoskeleton promote commitment to the osteoblastic over adipogenic lineage. β-catenin plays a critical role in the Wnt signaling pathway to facilitate downstream effects on gene expression. We show that β-catenin was additive with cytoskeletal signals to prevent adipogenesis, and β-catenin knockdown promoted adipogenesis even when the actin cytoskeleton was depolymerized. β-catenin also prevented osteoblast commitment in a cytoskeletal-independent manner, with β-catenin knockdown enhancing lineage commitment. Chromatin immunoprecipitation (ChIP)-sequencing demonstrated binding of β-catenin to the promoter of enhancer of zeste homolog 2 (EZH2), a key component of the polycomb repressive complex 2 (PRC2) complex that catalyzes histone methylation. Knockdown of β-catenin reduced EZH2 protein levels and decreased methylated histone 3 (H3K27me3) at osteogenic loci. Further, when EZH2 was inhibited, β-catenin's anti-differentiation effects were lost. These results indicate that regulating EZH2 activity is key to β-catenin's effects on BMSCs to preserve multipotentiality. © 2020 American Society for Bone and Mineral Research.
Subdural hematoma from an acquired dural arteriovenous fistula following external ventricular drain placement for subarachnoid hemorrhage
Kerezoudis, Panagiotis , Sorenson, Thomas J. , Kapurch, Joseph, Link, Michael J., Cloft, Harry J. , Kapurch, Joseph R, Wijdicks, Eelco F., Cloft, Harry, Link, Michael J. , Wijdicks, Eelco F. M. , Gompel, Jamie J. Van

Mayo Clinic

International Journal of Neuroscience | February 5, 2020 | Volume: 130 | Issue: 11 | Pages: 1166-1169

10.1080/00207454.2020.1722663 | PMID 32019398 Get It

FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements.
Furuse, Junji , Ioka, Tatsuya , Lihou, Christine , Féliz, Luis , Asatiani, Ekatherine, Jiang, Ping , Bekaii‐Saab, Tanios , Valle, Juan W. , Cutsem, Eric Van , Rimassa, Lorenza , Furuse, Junji , Melisi, Davide , Macarulla, Teresa , Bridgewater, John , Wasan, Harpreet , Borad, Mitesh J. , Zhen, Huiling, Vogel, Arndt

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: TPS592-TPS592

10.1200/jco.2020.38.4_suppl.tps592 Get It

TPS592 Background: For advanced CCA, standard of care 1L systemic treatment is GEM + CIS. Genetic alterations in intrahepatic CCA provide potential therapeutic targets. Fibroblast growth factor receptor (FGFR) 2 gene rearrangements driving CCA tumorigenesis were identified almost exclusively in intrahepatic CCA patients (pts) (incidence, 10–16%). In phase 2, PEM (INCB054828), a selective, potent, oral FGFR1–3 inhibitor elicited an objective response rate (ORR) of 35.5% and median progression-free survival (PFS) of 6.9 months (mo) in previously treated, locally advanced or metastatic CCA with FGFR2 rearrangements (NCT02924376). FIGHT-302, a randomized, open-label, phase 3 study will evaluate efficacy and safety of 1L PEM vs GEM + CIS in unresectable/metastatic CCA with FGFR2 fusions or rearrangements (NCT03656536). Methods: Eligible pts are adults with confirmed unresectable/metastatic CCA; no prior systemic therapy for advanced disease < 6 mo before enrollment; radiographically measurable/evaluable disease (per RECIST v1.1); ECOG PS ≤1; documented FGFR2 fusions or rearrangements. Exclusions include clinically significant corneal or retinal disorder; history of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic soft tissue calcification; untreated CNS metastases or history of uncontrolled seizures. Pts will be randomized (1:1; stratified by region and tumor burden) to PEM 13.5 mg QD on a 21-day (d) cycle or GEM (1000 mg/m2) + CIS (25 mg/m2) on D1 and D8 of 21-d cycles (max 8). Crossover to PEM allowed after confirmed progression. PEM titration to 18 mg from cycle 2 allowed for pts without hyperphosphatemia (serum phosphate > 5.5 mg/dL) and Grade ≥2 treatment-related adverse events during cycle 1. Hyperphosphatemia will be managed with diet modifications, phosphate binders, diuretics, or dose adjustments. Treatment will continue until progression or unacceptable toxicity. Primary endpoint is PFS (by independent review). Secondary endpoints are ORR, overall survival, duration of response, disease control rate, safety, and quality of life. Four pts (target N = 432) are enrolled as of Sep 25, 2019. Clinical trial information: NCT03656536.
How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.
Tournigand, Christophe , Lopes, Guilherme, Olswold, Curtis L., Goldberg, Richard M. , Hurwitz, Herbert I. , Bokemeyer, Carsten , Fuchs, Charles S. , Gramont, Aimery de , Adams, Richard , Zalcberg, John , Cutsem, Eric Van , Saltz, Leonard B. , Chibaudel, Benoist , Grothey, Axel , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 89-89

10.1200/jco.2020.38.4_suppl.89 Get It

89 Background: Monitoring of adverse events (AE) is crucial in clinical trials. Maximum grade per patient (pt) is commonly used but better metrics are needed to aid describing and comparing AE profiles. Methods: We developed and evaluated 2 longitudinal AE summary metrics. 1) Onset time of max grade refers to whether a pt has max grade within pre-specified timeframes for an AE, e.g. onset can be defined as “early” (max grade before the 6th cy) or “late” (≥ 6th cy). 2) Adverse effect load (AEL) is a longitudinal score of worst grade possible excluding death over the entire treatment for an AE. Higher AEL means worst overall experience of AE. We applied these metrics to real trial data. Pts were from 6 mCRC trials included in ARCAD database and received Irinotecan-based (n = 1,119) or Oxaliplatin-based (n = 1,230) treatments that did not include biologicals. AEs were diarrhea, nausea/vomiting, neutropenia/leukopenia, and neuropathy. We used linear model to AEL and logistic model to the other metrics, adjusting for age, sex, and number of metastases. Results: For nausea/vomiting, pts in Oxali-based chemo showed a higher AEL compared to patients in Iri-based (mean (M) [standard deviation (SD)] = 0.04 [0.06] vs. 0.02 [0.04]; p < 0.001) even though less pts had gr ≥ 3 (10.4% vs. 16.2%, resp.; p < 0.001), suggesting a lower-grade but persistent nausea/vomiting for Oxali-based. Among pts with diarrhea max gr 2, pts in Iri-based had higher AEL than with Oxali-based (M [SD] = 0.11 [0.11] vs. 0.08 [0.09]; p = 0.008), indicating more persistent diarrhea for Iri-based trts even among pts with same max grade. For neutropenia/leukopenia, pts in Oxali-based trts experienced higher AEL (M [SD] = 0.09 [0.13] vs. 0.05 [0.11], p < 0.001), and more pts in Oxali-based trts had gr ≥ 3 (70.1% vs. 64.4%; p = 0.002), suggesting that pts in Oxali-based trts experienced worst overall and max grade neutropenia/leukopenia compared to pts in Iri-based. Conclusions: To improve toxicity assessment in clinical trials, AEL and onset time of max grade are new measures that describe the evolution of adverse events over time. Further validation is warranted.